IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA issues warning letter to API manufacturer in Japan

10:03 AM MDT | April 5, 2013 | Deepti Ramesh

US FDA issued a warning letter late last month to the active pharmaceutical ingredient (API) manufacturing facility of Asada Milling Co. (Kanra, Japan), for deviating from cGMP. An FDA inspection of the Kanra API facility from 9–12 October 2012 identified significant deviations from cGMP for the manufacture of APIs, FDA says. The violations for the manufacture of APIs at the Kanra site include failure to perform quality-control-related activities, failure to maintain and clean manufacturing equipment and facilities, failure to establish written procedures...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa